-
HyperFusion™ Polymerase for Neurogenomics
2026-09-07
See how a proofreading DNA polymerase can strengthen sequence-validation workflows in C. elegans neurobiology. This article connects HyperFusion™ PCR performance with the assay decisions needed to study pheromone-dependent neurodegeneration, while separating product capabilities from biological conclusions.
-
LINC01278–mTOR Signaling in Uveal Melanoma
2026-09-05
The 2023 reference study identifies LINC01278 as an autophagy-related long noncoding RNA that suppresses uveal melanoma progression through inhibition of the mTOR signaling pathway. By combining bioinformatics, cellular assays, pharmacological pathway perturbation, and a xenograft model, the work links an RNA regulator to a therapeutically relevant autophagy mechanism.
-
Testosterone Bounce and Prognosis After Degarelix
2026-09-05
A 2024 retrospective study identified a testosterone trajectory, termed testosterone bounce, that was associated with favorable overall and cancer-specific survival in prostate cancer patients treated with degarelix. The finding extends testosterone biomarker research beyond a single castration threshold, although its retrospective design means prospective validation is needed before clinical adoption.
-
Structure-Based Design of the MNK1/2 Inhibitor eFT508
2026-09-04
The reference study describes a crystal-structure-guided strategy that produced eFT508, a potent and highly selective dual MNK1/2 inhibitor built around a previously unreported pyridone–aminal scaffold. By suppressing MNK-dependent eIF4E phosphorylation, the compound provided pharmacologic evidence that dysregulated translation can be targeted in lymphoma and solid-tumor models.
-
Taltirelin Acetate: Mechanism and Research Uses
2026-09-04
Taltirelin acetate is a long-acting TRH analog used in neuroendocrine, neuroprotection, Parkinson’s disease, itch, and sleep-related preclinical research. Rat studies show that taltirelin produces sustained hypoglossal motor activation, supporting further investigation in obstructive sleep apnea models.
-
LY364947 for Reproducible TGF-β Assays
2026-09-03
Learn how LY364947, SKU B2287, can help distinguish TGF-β pathway modulation from nonspecific cytotoxicity in viability, proliferation, and EMT experiments. This scenario-based guide covers solvent control, Smad2 readouts, assay timing, vendor evaluation, and the limits of translating preclinical evidence across models.
-
BQCA Workflows for M1 Receptor Signaling
2026-09-03
BQCA provides a selective way to amplify acetylcholine-driven M1 receptor signaling without relying on broad muscarinic activation. This guide translates BQCA pharmacology into reproducible BRET, cellular signaling, electrophysiology, and neuroscience workflows, with practical controls for interpreting receptor bias and assay failure.
-
AZD8055: Practical mTOR Inhibitor Guide
2026-09-02
AZD8055 is a selective ATP-competitive mTOR inhibitor for controlled studies of mTORC1 signaling, mTORC2 signaling, cancer cell proliferation, and selected metabolic endpoints. It is best suited to preclinical mechanistic workflows, not clinical efficacy studies or experiments requiring a water-soluble compound.
-
Artesunate: Mechanisms and Cancer Research Use
2026-09-02
Artesunate is an artemisinin derivative with reported ferroptosis and caspase-11-related pyroptosis activity in cancer research models. Its value is strongest when concentration, solvent, exposure conditions, and separate growth-arrest and cell-death endpoints are documented.
-
TH287: Mapping MTH1-Dependent Cancer Vulnerability
2026-09-01
TH287, a potent MTH1 inhibitor, exposes how oxidized nucleotide stress can become a selective cancer-cell liability. This article presents a cell-state and assay-interpretation framework that extends beyond simple radiosensitization endpoints.
-
β-Elemene Inhibits Adipogenesis via AMPK in 3T3-L1
2026-09-01
The reference study identifies β-Elemene as an inhibitor of MDI-induced adipogenesis and insulin-resistance-associated changes in 3T3-L1 cells. Its main contribution is linking reduced lipid accumulation and restored glucose consumption with regulation of the AMPK pathway, while also defining a practical in vitro workflow for metabolic research.
-
Pol II Degradation and Transcription-Independent Cell Death
2026-08-31
The bioRxiv preprint argues that degrading RNA polymerase II (Pol II) activates cell death through mechanisms that cannot be explained solely by loss of transcription. Its main contribution is a conceptual and experimental separation of Pol II’s transcriptional function from a distinct survival-associated role, with implications for interpreting targeted protein-degradation studies.
-
JNJ-26854165: From p53 Mechanism to Translation
2026-08-30
A translational framework for using JNJ-26854165 (Serdemetan) to interrogate HDM2–p53 biology, distinguish growth arrest from cell killing, and design more informative radiosensitization studies.
-
MRTFA-KCNMB1 Control of Cancer Cell Stiffness
2026-08-29
Gajda et al. identify potassium efflux and the BK-channel auxiliary subunit KCNMB1 as regulators of cancer-cell stiffness downstream of MRTFA. Their integrated genetic, biophysical, electrophysiological, immune-cell, transcriptomic, and mouse-model data connect cancer-cell softening with immune evasion and metastatic colonization, while supporting BK-channel activation as a mechanistically actionable strategy.
-
Spatial Metabolomics of POCD Hippocampal Lipids
2026-08-29
The reference study combines spatial metabolomics, enzyme imaging, ultrastructural analysis, and pharmacological rescue to connect hippocampal lipid disruption with postoperative cognitive dysfunction after cardiopulmonary bypass in rats. Its findings implicate CA1 lipid accumulation and altered iPLA2–SPT regulation while showing that DHA and myriocin can partially normalize metabolic and behavioral outcomes in this model.